Repligen corp stock.
Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 30.36% in the past year. Currently, Repligen Corp’s price-earnings ratio is 58.9. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.
Total revenue as reported for the full year 2022 increased to $801.5 million compared to $670.5 million for the full year 2021, a year-over-year gain of 20%, or 25% at constant currency, overall ...Repligen Corporation Common Stock (RGEN) Stock Price, Quote, News & History | Nasdaq MY QUOTES: RGEN Edit my quotes Repligen Corporation Common Stock (RGEN) 0 Add to Watchlist...UPDATE – Repligen Announces Publication of the Company’s 2022 Sustainability Report. November 14, 2023. Our mission is to inspire advances in bioprocessing as a trusted partner in the production of biologic drugs that improve human health worldwide. Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 30.36% in the past year. Currently, Repligen Corp’s price-earnings ratio is 63.5. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.As of February 22, 2023, Repligen Corp had a $9.9 billion market capitalization, compared to the Medical Equipment, Supplies & Distribution median of $330.1 million. Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 5.92% in the past year. Currently, Repligen Corp’s price-earnings ratio is 58.8.
Reports first quarter revenue of $182.7 million, with base business growth of 4% as reported and 7% at constant currency Reports first quarter gross margin of 55.2% on both GAAP and adjusted (non-GAAP) basis Closed on acquisition of single-use bag manufacturer FlexBiosys Inc. in April WALTHAM, Mass., May 02, 2023 (GLOBE …Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 30.36% in the past year. Currently, Repligen Corp’s price-earnings ratio is 58.9. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.
Repligen Corp stock has a Value Score of 5, Growth Score of 82 and Momentum Score of 41. Comparing Premier Inc and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance …On November 14, 2023, Repligen Corporation (NASDAQ:RGEN) stock closed at $153.79 per share. One-month return of Repligen Corporation (NASDAQ:RGEN) was 7.92%, and its shares lost 19.47% of their ...
Repligen Corp’s Stock Price as of Market Close. As of April 28, 2023, 4:00 PM CST, Repligen Corp’s stock price was $151.63. Repligen Corp is up 4.46% from its previous closing price of $145.15. During the last market session, Repligen Corp’s stock traded between $144.20 and $149.36.UPDATE – Repligen Announces Publication of the Company’s 2022 Sustainability Report. November 14, 2023. Our mission is to inspire advances in bioprocessing as a trusted partner in the production of biologic drugs that improve human health worldwide. As President and CEO at REPLIGEN CORP , Tony J. Hunt made $7,713,930 in total compensation. Of this total $800,000 was received as a salary, $785,440 was received as a bonus, $1,623,698 was received in stock options, $4,499,792 was awarded as stock and $5,000 came from other types of compensation. This information is according to proxy ...Repligen Corporation is a life sciences company, which develops and commercializes bioprocessing technologies and systems that rises flexibility in the process of manufacturing biological drugs. The Company's bioprocessing business consist of four franchises, filtration; chromatography; process analytics; and proteins.
Repligen Corp. historical stock charts and prices, analyst ratings, financials, and today’s real-time RGEN stock price.
Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 18.68% in the past year. Currently, Repligen Corp’s price-earnings ratio is 60.4. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.
Repligen Corp ( RGEN) receives a weak valuation ranking of 32 from InvestorsObserver data analysis. The proprietary ranking system focuses on the underlying health of a company through analysis of its stock price, earnings, and growth rate. RGEN has a better value than 32% of stocks based on these valuation analytics.The number of shares of the Company's common stock, $0.01 par value per share ("Common Stock"), entitled to vote at the Annual Meeting was 55,429,107. The number of shares of Common Stock present or represented by valid proxy at the Annual Meeting was 51,525,212, representing 92.96% of the total number of shares of Common Stock entitled to vote ...A high-level overview of Repligen Corporation (RGEN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Total revenue as reported for the full year 2022 increased to $801.5 million compared to $670.5 million for the full year 2021, a year-over-year gain of 20%, or 25% at constant currency, overall ...45.74%. Dividend Yield. N/A. When it delivered its Q4 2022 report back in February, Repligen warned investors that in 2023, it expects a dip in revenue of between $1.5 million and $40 million due ...Repligen Company Info. Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs.The number of shares of the Company's common stock, $0.01 par value per share ("Common Stock"), entitled to vote at the Annual Meeting was 55,429,107. The number of shares of Common Stock present or represented by valid proxy at the Annual Meeting was 51,525,212, representing 92.96% of the total number of shares of Common …
Find the latest Repligen Corporation (RGEN) stock quote, history, news and other vital information to help you with your stock trading and investing. Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 22.3% in the past year. Currently, Repligen Corp’s price-earnings ratio is 64.0. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Repligen Corp stock has a Growth Score of 82, Estimate Revisions Score of 39 and Quality Score of 71. Comparing Steris PLC and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk ...Repligen Announces Publication of the Company’s 2022 Sustainability Report November 14, 2023TipRanks. Repligen price target lowered to $150 from $165 at Deutsche Bank November 7, 2023TipRanks ...Repligen Corp’s Stock Price as of Market Close. As of March 03, 2023, 4:00 PM CST, Repligen Corp’s stock price was $188.00. Repligen Corp is up 4.17% from its previous closing price of $180.48. During the last market session, Repligen Corp’s stock traded between $171.57 and $184.29.Feb 22, 2023 · Total revenue as reported for the full year 2022 increased to $801.5 million compared to $670.5 million for the full year 2021, a year-over-year gain of 20%, or 25% at constant currency, overall ... Get real-time Repligen (RGEN) stock price quotes, analyst insights, forecasts, news, and information you need to help your stock trading and investing.
... Stock Ideas · Long Ideas · Healthcare. Revisiting Repligen. May 11, 2022 11:31 AM ETRepligen Corporation (RGEN)7 Comments 3 Likes. Another Mountain's ...
NASDAQ does not use this value to determine compliance with the listing requirements. Repligen Corporation Common Stock (RGEN) Stock Quotes - Nasdaq offers stock quotes & market activity data for ...When starting a business, one of the most critical decisions you’ll have to make is choosing the right legal structure. Limited Liability Companies (LLCs) and S Corporations (S Corps) are two popular options for entrepreneurs, each with its...Repligen's (NASDAQ:RGEN) stock is up by a considerable 17% over the past month. We wonder if and what role the company's financials play in that price …Apr 21, 2020 · However, Repligen stock has ramped up nearly 33% in the aftermath, slightly outperforming even a bullish 30% gain for its medical products peers. Janney analyst Paul Knight expects the company to ... UPDATE – Repligen Announces Publication of the Company’s 2022 Sustainability Report. November 14, 2023. Our mission is to inspire advances in bioprocessing as a trusted partner in the production of biologic drugs that improve human health worldwide.Aug 2, 2022 · Shares of the bioprocessing giant Repligen Corporation ( RGEN 4.89%) are glowing green today. Specifically, the biotech's stock was up by as much as 14.9% earlier today. Repligen's shares have ... The Growth Grade Winner: Repligen Corp. As you can clearly see from the Growth Grade breakdown above, Repligen Corp has a more attractive growth grade than Bio Rad Laboratories Inc. For investors who focus solely on how a company is growing relative to other companies in the same industry, Repligen Corp could be a good stock to add to their ...
... shares relative to the market in the next few months. In addition, Repligen Corporation has a VGM Score of F (this is a weighted average of the individual ...
Discover historical prices for RGEN stock on Yahoo Finance. View daily, weekly or monthly format back to when Repligen Corporation stock was issued.
Repligen Corp. Stock , RGEN 157.24 -0.01 -0.00% After-market 04:44:59 PM EDT 11/30/2023 NAS Add to watchlist 157.25 -2.24 -1.40% Official Close 04:00:00 …Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 2.91% in the past year. Currently, Repligen Corp’s price-earnings ratio is 65.0. Repligen Corp’s trailing 12-month revenue is $801.3 million with a 20.8% net profit margin. Year-over-year quarterly sales growth most recently was 12.6%.Repligen Corp stock has a Value Score of 4, Momentum Score of 73 and Quality Score of 72. Comparing Becton Dickinson and Co and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as …With its stock down 4.8% over the past month, it is easy to disregard Repligen (NASDAQ:RGEN). However, stock prices are usually driven by a company’s financials over the long term, which in this ...Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 15.77% in the past year. Currently, Repligen Corp’s price-earnings ratio is 65.8. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Repligen Corp ( RGEN) receives a weak valuation ranking of 32 from InvestorsObserver data analysis. The proprietary ranking system focuses on the underlying health of a company through analysis of its stock price, earnings, and growth rate. RGEN has a better value than 32% of stocks based on these valuation analytics.Oct 13, 2023 · Repligen Corp stock has a Growth Score of 82, Estimate Revisions Score of 38 and Quality Score of 71. Comparing Abbott Laboratories and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. Discover historical prices for RGEN stock on Yahoo Finance. View daily, weekly or monthly format back to when Repligen Corporation stock was issued. Repligen Corporation is a life sciences company, which develops and commercializes bioprocessing technologies and systems that rises flexibility in the process of manufacturing biological drugs. The Company's bioprocessing business consist of four franchises, filtration; chromatography; process analytics; and proteins.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 27.1% in the past year. Currently, Repligen Corp’s price-earnings ratio is 68.5. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.
RGEN | Complete Repligen Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 22.25% in the past year. Currently, Repligen Corp’s price-earnings ratio is 66.4. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Repligen Corp. shares valued at $557,328 were sold by Gebski Christine on Nov 10. At $147.13 per share, Gebski Christine sold 3,788 shares.Instagram:https://instagram. nutrien stocksbest crypto auto trading platformigv etfdebt management classes Sep 18, 2023 · Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 27.1% in the past year. Currently, Repligen Corp’s price-earnings ratio is 68.5. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%. best fertility insurancenvda short etf Feb 28, 2023 · Repligen Corp’s trailing 12-month revenue is $801.5 million with a 23.2% net profit margin. Year-over-year quarterly sales growth most recently was 0.2%. Analysts expect adjusted earnings to reach $2.678 per share for the current fiscal year. Repligen Corp does not currently pay a dividend. How We Compare DexCom, Inc. and Repligen Corp Stock ... can i buy crypto on cash app Repligen Corp stock has a Value Score of 5, Growth Score of 82 and Momentum Score of 69. Comparing AmerisourceBergen Corp. and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not.Summary. Deutsche Bank Cuts Repligen Price Target to $150 From $165, Maintains Hold Rating. Nov. 07. MT. Repligen Corporation to Present at Upcoming Investor Conferences. Nov. 07. AQ. CORRECTION : RBC Trims Price Target on Regeneron Pharmaceuticals to $837 From $847, Keeps Sector Perform Rating. Nov. 03.